New Test Predicts Lymphoma Patient Treatment Outcomes
Researchers discovered a way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.
Researchers discovered a way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.
Bluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
New 10-color system with Kaluza C software streamlines workflow and QC reporting for flow cytometry in leukemia and lymphoma analysis.
HTG’s next-generation sequencing assay enables subtyping of DLBCL as activated B-cell-like or germinal center B-cell-like.
Read MoreUnder a new grant from the National Cancer Institute, Advanced Cell Diagnostics will partner with the Cleveland Clinic to develop an ultrasensitive diagnostic test for B-cell lymphoma.
Read MoreA new collaboration plans to provide genomic profiling and information for patients that have been unsuccessful on repeated therapy for the group of cancers that include leukemias, lymphomas, and myeloproliferative and myelodysplastic diseases.
Read MoreA new study shows the MultiOmyx profile could improve disease assessment for both diseases using multiplex proteins.
Read MoreUltra-sensitive detection of minimal residual disease now available to more people with blood cancers.
Read MoreAssay can aid physicians in better risk stratification and treatment of patients with diffuse large B-cell lymphoma.
Read MoreThe test has been shown to offer sensitivity for the detection of residual cancer cells in marrow or blood.
Read MoreWith so many types of lymphoma, there’s a wide range of corresponding lab tests to detect their presence in patients. Here, CLP takes a look at testing for the most common type of lymphoma (diffuse large B-cell
Read More